Blood replenishing medicine composition and preparing method thereof
A composition and drug technology, applied in the direction of drug combination, medical formula, blood diseases, etc., can solve the problems of high price, complicated process, and insignificant effect, and achieve the effect of low cost, broad application prospect, and remarkable and reliable curative effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0027] A blood-enriching pharmaceutical composition, which is prepared from the following raw materials in weight ratio:
[0028] Angelica 45 parts, Ophiopogon japonicus 45 parts, Jujube 45 parts, Astragalus membranaceus 45 parts, Polygonum multiflorum 40 parts,
[0029] 40 parts of cinnamon, 40 parts of mulberry, 40 parts of privet fruit, 35 parts of raspberry, 35 parts of Atractylodes macrocephala,
[0030] 35 parts of papaya, 35 parts of licorice, 35 parts of poria cocos, 30 parts of dandelion, 30 parts of Sijiqing,
[0031] 30 parts of frankincense, 30 parts of rehmannia, 30 parts of comfrey, 25 parts of jujube seed, 25 parts of myrrh,
[0032] Guizhi 25 parts, Salvia miltiorrhiza 20 parts, Morinda officinalis 20 parts, Lycium barbarum 20 parts, Albizia juniper bark 20 parts, Coix seed 20 parts.
[0033] The preparation method of described pharmaceutical preparation is as follows:
[0034] Take by weighing above-mentioned crude drug according to above-mentioned weight f...
Embodiment 2
[0040] Toxicity test:
[0041] In this experiment, healthy SD rats were used, and the dosage gradient of the drug prepared in Example 1 was administered orally at 0.01g / kg and 0.1g / kg, and the drug was administered continuously for 30 days. Animal growth status, activity diet, hematology, blood biochemistry, organ tissue structure and urine routine were not significantly affected, indicating that the clinical medication is safe and reliable.
Embodiment 3
[0043] Summary of clinical efficacy:
[0044] General information, the pharmaceutical preparation of the present invention is applied to 98 cases of clinical observation, and all subjects are divided into 2 groups on average, control group and experimental group, each group of 49, two groups of cases in terms of gender, age, course of disease, etc. Analysis is comparable.
[0045] The diagnostic criteria formulated by WHO in 1972 considered that anemia was diagnosed when Hb was lower than the following levels in sea level areas: 110g / L for children aged 6 months to <6 years, 120g / L for children aged 6-14, 130g / L for adult males, and 130g / L for adults. 120g / L for women and 110g / L for pregnant women. It should be noted that the normal hemoglobin value of residents living in plateau areas is higher than that of sea-level residents; during pregnancy, hypoalbuminemia, congestive heart failure, splenomegaly, and macroglobulinemia, plasma volume increases, and even red blood cells ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com